|
Subsequent Events (Details Textual) (USD $)
|
0 Months Ended | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|---|
|
Mar. 15, 2011
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
|
| Royalty Revenue | $ 3,000,000 | $ 0 | $ 1,228,000 | $ 1,424,000 | $ 3,816,000 |
|
Subsequent Event [Member] | Maximum [Member]
|
|||||
| Revenue Recognition, Milestone Method, Revenue Recognized | 165,000,000 | ||||
| Royalty Revenue | 50,000,000 | ||||
|
Subsequent Event [Member] | Minimum [Member]
|
|||||
| Revenue Recognition, Milestone Method, Revenue Recognized | 130,000,000 | ||||
|
Subsequent Event [Member] | Braeburn [Member]
|
|||||
| Equity Method Investment, Aggregate Cost | 5,000,000 | 5,000,000 | |||
| Stock Issued During Period, Shares, New Issues | 6,250,000 | ||||
| Stock Issued During Period, Value, New Issues | 5,000,000 | ||||
| Common Stock, Par or Stated Value Per Share | $ 0.80 | $ 0.80 | |||
|
Subsequent Event [Member] | Probuphine® [Member] | Maximum [Member]
|
|||||
| Revenue Recognition, Milestone Method, Revenue Recognized | 45,000,000 | ||||
|
Subsequent Event [Member] | Probuphine® [Member] | Minimum [Member]
|
|||||
| Revenue Recognition, Milestone Method, Revenue Recognized | $ 15,000,000 | ||||